A novel infant microbiome formula (SIM03) improved eczema severity and quality of life in preschool children

• Published in: Scientific reports Vol. 14; no. 1; p. 3168
• Main Authors: Chan, Oi Man, Xu, Wenye, Cheng, Nam Sze, Leung, Agnes Sze Yin, Ching, Jessica Yuet Ling, Fong, Brian Leong Yuen, Cheong, Pui Kuan, Zhang, Lin, Chan, Francis Ka Leung, Ng, Siew Chien, Leung, Ting Fan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779; 692/308/3187; 692/699/4033; Acetic acid; Atopic dermatitis; Bifidobacterium; Bifidobacterium bifidum; Child; Child, Preschool; Children; Dermatitis; Dermatitis, Atopic - microbiology; Dermatitis, Atopic - therapy; Eczema; Eczema - therapy; Gastrointestinal Microbiome - genetics; Gut microbiome; Humanities and Social Sciences; Humans; Infant; Infants; Intestinal microflora; Metagenomics; Microbiomes; Microencapsulation; multidisciplinary; Pilot Projects; Probiotic; Quality of Life; Relative abundance; Science; Science (multidisciplinary); Skin diseases; Probiotic; Bifidobacterium; Children; Atopic dermatitis; Gut microbiome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-53848-w

Altered gut microbiome composition has been reported in children with eczema and interventions that restore beneficial bacteria in the gut may improve eczema. This open-label pilot study aimed to investigate the efficacy of a novel infant microbiome formula (SIM03) in young children with eczema. Pre-school Chinese children aged 1–5 years old with eczema received SIM03 twice daily for three months. The novelty of SIM03 consists of both the use of a patented microencapsulation technology to protect the viability of unique Bifidobacterium bifidum and Bifidobacterium breve strains identified through big data analysis of large metagenomic datasets of young Chinese children. Paired stool samples at baseline and following SIM03 were analyzed by metagenomics sequencing. Generalized estimating equation was used to analyze changes in eczema severity, skin biophysical parameters, quality of life and stool microbiome. Twenty children aged 3.0 ± 1.6 years (10 with severe eczema) were recruited. Treatment compliance was ≥ 98%. SCORing Atopic Dermatitis score decreased significantly at two months ( P  = 0.008) and three months ( P  < 0.001), while quality of life improved significantly at 1, 2, and 3 months. The relative abundance of B. breve and microbial pathways on acetate and acetyl-CoA synthesis were enriched in stool samples at one month ( P  = 0.0014). Children who demonstrated increased B. bifidum after SIM03 showed improvement in sleep loss ( P  = 0.045). Relative abundance of B. breve correlated inversely with eczema extent ( P  = 0.023) and intensity ( P  = 0.019) only among patients with increased B. breve at Month 3. No serious adverse event was observed. In conclusion, SIM03 is well tolerated. This patented microbiome formula improves disease severity and quality of life in young eczematous children by enhancing the delivery of B. bifidum and B. breve in the gut. SIM03 is a potential treatment option for childhood eczema.